Dendritic Cell Vaccination

Titlesort descending Average Rating
71 year old woman, Pancraetic cancer with liver and lung metastasis. 90.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
A phase I trial of tumor-associated antigen-pulsed dendritic cell immunotherapy for patients with brain stem glioma and glio.... 60.00%
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. 85.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli 70.00%
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. 90.00%
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy 90.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%
Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. 80.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: 90.00%
Immunotherapy with dendritic cells as a second-line therapy in advanced pleural mesothelioma. 90.00%
Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus. 100.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Therapeutic vaccination against advanced pancreatic cancer by autologous dendritic cells pulsed with a MUC1 peptide: Preclinic.. 60.00%
Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in ........ 80.00%